SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards. Its professional team includes translators, terminologists, linguistic engineers, IT experts, technical editors and graphic designers. The Company’s production offices and management departments are located in Argentina, Spain, Uruguay and Panama. The Company offers translations within a range of fields such as legal, financial, business, economy, and health sciences, marketing, advertising and technical. It translates and adapts all of the customer’s software products, such as resource files, online help, printed documentation, including compilation and testing of various components.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolAMEX:SLS
CUSIPN/A
Phone+1-417-8834549
Debt
Debt-to-Equity RatioN/A
Current Ratio0.95
Quick Ratio0.95
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.89 per share
Price / Book0.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-23,540,000.00
Net Margins-51.98%
Return on Equity-89.41%
Return on Assets-41.06%
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
SLS International (AMEX:SLS) Frequently Asked Questions
What is SLS International's stock symbol?
SLS International trades on the AMEX under the ticker symbol "SLS."
How were SLS International's earnings last quarter?
SLS International Inc (AMEX:SLS) posted its earnings results on Wednesday, May, 10th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.13. SLS International had a negative net margin of 51.98% and a negative return on equity of 89.41%. During the same period in the prior year, the firm posted ($0.07) earnings per share. View SLS International's Earnings History.
What price target have analysts set for SLS?
3 Wall Street analysts have issued 12-month price targets for SLS International's stock. Their forecasts range from $11.00 to $13.00. On average, they expect SLS International's stock price to reach $12.00 in the next twelve months. View Analyst Ratings for SLS International.
What are Wall Street analysts saying about SLS International stock?
Here are some recent quotes from research analysts about SLS International stock:
- 1. According to Zacks Investment Research, "SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. " (6/15/2018)
- 2. Maxim Group analysts commented, "The prior interim data readout for the P2b trial, specifically in patients with triple negative breast cancer (TNBC), evaluating NeuVax + Herceptin demonstrated efficacy and continued safety. Board (DSMB) recommended pursuing TNBC. As such, the P2b trial has been halted and Sellas is in discussions with regulators regarding an optimal path forward to take the NeuVax + Herceptin combination to a pivotal trial." (6/1/2018)
Who are SLS International's key executives?
SLS International's management team includes the folowing people:
- Angelos M. Stergiou M.D., President, Chief Executive Officer, Director
- Aleksey N. Krylov, Interim Chief Financial Officer, Treasurer
- Nicholas J. Sarlis M.D. Ph.D., Chief Medical Officer, Senior Vice President
- Gregory M. Torre Ph.D. J.D., Chief Regulatory Officer, Senior Vice President
- John Thomas Burns, Vice President - Finance, Corporate Controller
- Fabio Lopez, Director
- David A. Scheinberg, Director
- Stephen F. Ghiglieri, Independent Director (Age 55)
- Robert L. Van Nostrand, Independent Director
- John Varian, Independent Director
Has SLS International been receiving favorable news coverage?
Media coverage about SLS stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SLS International earned a daily sentiment score of 0.13 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of SLS International?
Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SLS International's stock price today?
One share of SLS stock can currently be purchased for approximately $0.0008.
How big of a company is SLS International?
SLS International has a market capitalization of $33,893.00. SLS International employs 14 workers across the globe.
How can I contact SLS International?
SLS International's mailing address is 3119 S Scenic Ave, SPRINGFIELD, MO 65807-3926, United States. The biotechnology company can be reached via phone at +1-417-8834549 or via email at [email protected]
MarketBeat Community Rating for SLS International (SLS)
MarketBeat's community ratings are surveys of what our community members think about SLS International and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
